Tvardi Therapeutics flame icon

Current News

Newsroom V1

Latest Press Releases & Media News

Press Release

Tvardi Therapeutics to Present at the 35th Annual Piper Sandler Healthcare Conference

November 21, 2023
Press Release

Tvardi Therapeutics Announces First Patients Dosed in its Phase 2 Idiopathic Pulmonary Fibrosis Trial using TTI-101, a Novel STAT3 Inhibitor

August 31, 2023
Press Release

Tvardi Therapeutics Announces First Patients Dosed in its Phase 2 Liver Cancer Trial Using TTI-101, a Novel STAT3 Inhibitor

June 22, 2023
Press Release

Tvardi Therapeutics Announces Presentation of Data from the Phase 1 Trial of TTI-101, a STAT3 Inhibitor, in Advanced Solid Tumors at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

May 25, 2023
Press Release

Tvardi Therapeutics to Participate at the Cowen 43rd Annual Health Care Conference

February 28, 2023
Media

Tvardi Therapeutics Announces First Patients Dosed in Phase 2 Trial of TTI-101 in Metastatic Breast Cancer

February 23, 2023

Newsroom V2

Latest Press Releases

Press Release

Tvardi Therapeutics to Present at the 35th Annual Piper Sandler Healthcare Conference

November 21, 2023
Press Release

Tvardi Therapeutics Announces First Patients Dosed in its Phase 2 Idiopathic Pulmonary Fibrosis Trial using TTI-101, a Novel STAT3 Inhibitor

August 31, 2023
Press Release

Tvardi Therapeutics Announces First Patients Dosed in its Phase 2 Liver Cancer Trial Using TTI-101, a Novel STAT3 Inhibitor

June 22, 2023
All Press Releases

Latest Media

Media

New Phase 2 Study Set to Evaluate Oral TTI-101 in IPF

January 13, 2023
Media

FDA Grants Fast Track Designation to TTI-101 for Advanced Hepatocellular Carcinoma

October 19, 2022
Media

TTI-101 Receives FDA’s Orphan Drug Status for IPF

May 27, 2022
All Media

Newsroom V3

Latest Press Releases

All Press Releases

Latest Media

All Media

Newsroom V4

Latest Press Releases

More Press Releases

Latest Media

More Media

Latest Scientific Publications

More Press Releases
Media

New Phase 2 Study Set to Evaluate Oral TTI-101 in IPF

January 13, 2023
Media

FDA Grants Fast Track Designation to TTI-101 for Advanced Hepatocellular Carcinoma

October 19, 2022
Media

TTI-101 Receives FDA’s Orphan Drug Status for IPF

May 27, 2022
Scientific Publications

Drugging “Undruggable” Disease-Causing Proteins: Focus on Signal Transducer and Activator of Transcription (STAT) 3

December 31, 2022
Scientific Publications

Genetic and Small-Molecule Modulation of Stat3 in a Mouse Model of Crohn’s Disease

November 28, 2022
Scientific Publications

IL-6/JAK/STAT3 Signaling in Breast Cancer Metastasis: Biology and Treatment

March 15, 2022
Scientific Publications

Drugging “Undruggable” Disease-Causing Proteins: Focus on Signal Transducer and Activator of Transcription (STAT) 3

December 31, 2022
Scientific Publications

Genetic and Small-Molecule Modulation of Stat3 in a Mouse Model of Crohn’s Disease

November 28, 2022
Scientific Publications

IL-6/JAK/STAT3 Signaling in Breast Cancer Metastasis: Biology and Treatment

March 15, 2022
Scientific Publications

Drugging “Undruggable” Disease-Causing Proteins: Focus on Signal Transducer and Activator of Transcription (STAT) 3

December 31, 2022
Scientific Publications

Genetic and Small-Molecule Modulation of Stat3 in a Mouse Model of Crohn’s Disease

November 28, 2022
Scientific Publications

IL-6/JAK/STAT3 Signaling in Breast Cancer Metastasis: Biology and Treatment

March 15, 2022

We use cookies to ensure that we give you the best experience on our website. By using this website you agree to the Privacy Policy and  Terms of Use.

Accept & Close